APTO

In a report released on November 14, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aptose Biosciences (APTO - Research Report), with a price target of $12.00. The company's shares opened today at $0.65.According to TipRanks, Pantginis is an analyst with an average return of -16.5% and a 30.33% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, PDS Biotechnology, and Biomea Fusion.Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $7.33, a 1,027.69% upside from current levels.
https://www.tipranks.com/news/blurbs/aptose-biosciences-apto-gets-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral